CD19 and acute lymphoblastic leukemia: In four trials, 37 of 220 patients with ALL experienced CD19-negative relapse after treatments with CD19 Si-CAR T-cell therapy [10], with median follow-up ranging from 12 [55], 13.1 [3], 22.6 [56], to 29 months [57], respectively.